BÜHLMANN GanglioCombi® Light ELISA is a reduced profile of the BÜHLMANN GangliCombi® MAG ELISA for a targeted screening of antibodies against the most frequent gangliosides (GM1, GD1b and GQ1b). It includes the same calibrator and controls as the BÜHLMANN GangliCombi® MAG ELISA. Patients may be analysed for antibodies against each of these gangliosides so to obtain an IgG and IgM “mini-profile” per patient.
Anti-GM1 antibodies: anti-GM1 antibodies (IgG) are implicated in the pathogenesis of Guillain-Barré Syndrome (GBS) and anti-GM1 antibodies (IgM) in multifocal motor neuropathy (MMN) and motor neuron diseases (MND). anti-GM1 antibodies (IgM) may be present as monoclonal IgM paraprotein or as a polyclonal IgM. Polyclonal IgG may be detected in patients with motor neuropathies. High GM1 antibody titers may be detected in association with GBS following Campylobacter jejuni infection. The fact that GM1 is the only common Glycolipid antigen reactive with all of the GM1 antibodies found in motor nerve disorders suggests that it is the relevant target antigen in neural tissue.
Anti-GD1b antibodies: Reactivity against gangliosides containing disialosyl groups, particularly GD1b, has been reported in isolated cases of acute and chronic idiopathic ataxic neuropathies.
The clinical picture comprises a chronic neuropathy with marked sensory ataxia and areflexia and with relatively preserved motor function in the limbs. In addition many patients have preserved motor function. When present in their entirety, these clinical features are described under the acronym CANOMAD (chronic, ataxic, neuropathy, opthalmoplegia, IgM paraprotein, cold agglutinins, disialosy antibodies).
Anti-GQ1b antibodies: Anti- IgG GQ1b antibodies are closely associated with Miller-Fisher Syndrome (MFS), which is discussed to be a variant of Guillain-Barré Syndrome. Up to 100% of MFS patients have these antibodies. Anti-GQ1b antibodies decay rapidly with clinical recovery and usually are not found in normal and disease control samples (non-immune-mediated neuropathies). The close serologic-clinical association make anti-GQ1b antibodies in suspected cases of overlapping symdroms in neuropathies a useful diagnostic marker for physicians with therapeutic significance.
BÜHLMANN GanglioCombi® Light Product Information
|Time to Result
||4.5 h (approx.)
||20 µl serum (1:50)
||IgG/IgM mix and IgG, IgM